Study summary

An EGFR-MET antibody shrank tumors after other treatments failed

OrigAMI-1 trial (amivantamab) · 94 people, phase 1b/2 · Published June 2026, Journal of Clinical Oncology

29%of left-sided tumors shrank (no prior anti-EGFR drug)

What was tested

Amivantamab, an antibody against EGFR and MET first approved for lung cancer, given alone to people with RAS/BRAF wild-type metastatic colorectal cancer after 2 to 3 earlier treatments. No comparison group.

What they found

What it means

Now in two phase 3 trials against cetuximab-based treatment.

J Clin Oncol, via PubMed ↗ Trial record NCT05379595 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.